The goal of our studies is to generate durable CD8+ T cell responses against epithelial ovarian cancer (EOC) for extending remission rates. However, major obstacles to the development of effective immunotherapy exist including (i) inability to induce expansion of high avidity, tumor-antigen specific effector CD8+ T cells (ii) lack of tumor-antigen specific memory CD8+ T cells, and (iii) presence of CD4+CD25+FOXP3+ regulatory T cells. In previous studies, we have observed that although vaccine induced tumor antigen specific effector CD8+ T cells can provide tumor protection, they do not provide durable tumor immunity, which is typically afforded by memory T cells. We have also noted that rapamycin mediated inhibition of mammalian target of rapamycin (mTOR) switches effector CD8+ T cells to memory via regulation of transcriptional factors T-bet and Eomesodermin. Moreover, in our murine model, varying the duration (0-8, 0-20 or 0-40 days) of mTOR inhibition after immunization produces memory CD8+ T cells with varying extent of type 1 effector functions. Consequently, we hypothesize that by changing the regimen (dose and duration) of rapamycin administration in immunized ovarian cancer patients, we will generate high avidity CD8+ T cells with varying extent of effector functions for durable ovarian tumor immunity. Therefore, our objectives are to determine the regimen of mTOR inhibition, that in combination with viral vector immunization does not produce toxicity but generates optimal durable CD8+ T cell responses in a phase I clinical trial. Second, by varying the timing of rapamycin administration, we will determine the mechanisms by which mTOR inhibition produces functionally distinct memory CD8+ T cells of high avidity. To test our hypotheses, we propose: SA1: To determine the regimen (dose and duration) of mTOR inhibition that in combination with rCNP-NY-ESO-1/TRICOM immunization is safe and produces durable CD8+ T cell responses in a phase I clinical trial. SA2: To test whether the regimen of rapamycin administration after rCNP-NY-ESO-1/TRICOM immunization generates memory CD8+ T cells with varying extent of effector functions and antigen avidity. SA3: To determine the impact of rapamycin treatment regime on rCNP-NY-ESO-1/TRICOM induced CD4+ T cell response for CD8+ T cell memory generation. The successful completion of our proposed studies will result in the generation of critical data that will facilitate Phase II evaluation of mTOR inhibition to generate high avidity memory T cells, promote conditions that favor durable host immunity, and prolong disease free survival in ovarian cancer patients.

Public Health Relevance

There is increasing evidence that the immune system has the ability to recognize and kill ovarian and other human cancers. However, attempts at using cancer vaccines to engage the immune system to fight cancer cells have been disappointing because of (i) inability to generate long lasting immune responses (ii) suppression of immune cells by a specialized population of cells called regulatory T cells. In this study proposed, we plan to test a multi-modal approach of immunizing ovarian cancer patients by (i) using a viral based vaccine expressing three specialized molecules (TRICOM) to enhance immune reaction to NY-ESO-1 antigen, that is frequently expressed in ovarian cancers (ii) rapamycin to promote generation of memory immune cells that persist for a long time and thereby prevent relapse of ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA158318-04
Application #
8698342
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Song, Min-Kyung H
Project Start
2011-09-01
Project End
2016-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Szender, J Brian; Papanicolau-Sengos, Antonios; Eng, Kevin H et al. (2017) NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 145:420-425
Klinkebiel, David; Zhang, Wa; Akers, Stacey N et al. (2016) DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Mol Cancer Res 14:787-94
Seagle, Brandon-Luke L; Eng, Kevin H; Yeh, Judy Y et al. (2016) Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Sci Rep 6:21591
Szender, J Brian; Eng, Kevin H; Matsuzaki, Junko et al. (2016) HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol 142:158-162
Zhang, Wa; Barger, Carter J; Eng, Kevin H et al. (2016) PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget 7:45352-45369
Chaudhuri, Leena; Srivastava, Rupesh K; Kos, Ferdynand et al. (2016) Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD8+ T cells. Cancer Immunol Immunother 65:869-74
Brightwell, R M; Grzankowski, K S; Lele, S et al. (2016) The CD47 ""don't eat me signal"" is highly expressed in human ovarian cancer. Gynecol Oncol 143:393-397
Matsuzaki, Junko; Tsuji, Takemasa; Luescher, Immanuel F et al. (2015) Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep 5:14896
Khan, Anm Nazmul H; Kolomeyevskaya, Nonna; Singel, Kelly L et al. (2015) Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget 6:11310-26
Seagle, Brandon-Luke L; Yang, Chia-Ping Huang; Eng, Kevin H et al. (2015) TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecol Oncol 138:159-64

Showing the most recent 10 out of 22 publications